Dana-Farber/Brigham and Women's Cancer Care Collaborative
Learn More About The Collaborative
We’re here to help. If you have questions or need assistance, call 203.276.2695 or fill out our form.
The Bennett Cancer Center is proud to be a member of the Dana-Farber/Brigham and Women’s Cancer Care Collaborative, providing our staff and patients access to the latest and most effective, evidence-based best practices and standards in cancer treatment and research.
The Dana-Farber/Brigham and Women's Cancer Care Collaborative serves a select group of hospitals that have demonstrated a commitment to excellence by meeting a wide range of cancer care standards and best practices.
Dana-Farber and Brigham and Women’s clinicians and other specialists conducted an extensive and rigorous review of the Bennett Cancer Center’s outpatient adult medical and radiation oncology practices and procedures, including:
- Patient safety protocols
- Nursing and pharmacy practices
- Chemotherapy administration
- Information systems
Following review of their oncology operations, Collaborative members agree to implement key recommendations in order to meet Dana-Farber/Brigham and Women’s standards.
Dana-Farber/Brigham and Women’s Collaborative membership enhances educational opportunities for member hospitals' staffs; offers opportunities for members to consult with medical specialists at the Dana-Farber/Brigham and Women’s Cancer Center; and provides members with expedited access to their main campus in Boston for patients with complex cancers. Members can also take advantage of access to Dana-Farber/Brigham and Women’s support services, such as on-site specialty second opinion clinics, clinical trials, tumor board conferences, and physician lectures.
Frequently Asked Questions About the Collaborative
1. In brief, what does this opportunity mean for the Bennett Cancer Center’s model of care?
The relationship is a validation of the high quality of cancer care provided by Bennett Cancer Center. Most importantly, it brings the world-class resources of Dana-Farber Cancer Institute (DFCI) to the Stamford community.
2. Are more doors being opened to patients for newer clinical trials?
The goal is to open promising studies that would otherwise not be available.
3. Does this mean I’ll need to be sent to Boston to receive additional treatment?
Not necessarily. It means that our patients will often receive multiple opinions from world experts at DFCI at the tumor conferences that we have regularly with them. However, if there are very promising studies or treatments only available at DFCI and not available locally, then we may recommend going to Boston.
4. How do I find out if I, personally, can benefit from this collaborative?
All patients will benefit either directly or indirectly. Because of the collaboration, we have much easier access to the leaders of the field to ensure that we have considered all treatment options and that no stones are unturned. This opportunity also further improves overall quality of care.
5. What are some of the top scenarios in which one can directly benefit from this collaborative?
Sometimes in complicated cases, a patient can become very confused when he or she sees different oncologists and have different opinions. We can present such a case to the world experts at DFCI either at the tumor conferences or through direct communication with them. When 3 or 4 experts all feel strongly about one treatment, it helps the patient tremendously in choosing the right course for them. This peace of mind is priceless.